GleamWall
中文EN

OSTX OS Therapies Inc

Pharmaceutical Preparations · NYSE · SEC CIK 1795091 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-139.4%
TTM EPS YoY9.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-513.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets296.1%
Debt / equity—
Current ratio0.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-296.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$16.36M$2.84M
SG&A expense$12.34M$3.97M
Operating income-$28.71M-$6.81M
Interest expense—$2.05M
Net income-$28.75M-$8.88M
EBITDA-$28.34M-$6.81M
EPS (basic)-0.98-1.28
EPS (diluted)-0.98-1.28
Weighted avg. shares (diluted)29.25M6.95M
Banking
Deposits—$150,000
Balance sheet
Cash & equivalents$269,830$5.53M
Current assets$332,912$5.53M
PP&E, net$2,490$5,270
Intangibles$6.50M—
Total assets$6.84M$5.54M
Current liabilities$11.76M$4.63M
Total liabilities$11.86M$4.73M
Shareholders' equity-$6.10M-$3.27M
Shares outstanding37.11M20.87M
Cash flow statement
Operating cash flow-$14.24M-$7.28M
Capital expenditure$466,423—
Free cash flow-$14.70M—
Investing cash flow-$466,423—
Financing cash flow$9.44M$12.78M
Depreciation & amortization$363,085$2,780
Stock-based compensation$4.27M$268,300

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.